Cancer clinical trials in the region Île-de-France
737 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819735
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Domain Therapeutics Australia Pty Ltd
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06154291
#2023-505266-29-00
Partie I: Escalade de dose
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS
Phase 1 / Phase 2
Breast cancer
Lung cancer
Colon cancer
Rectal cancer
Pancreas cancer
Stomach and esophageal cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06154291
#2023-505266-29-00
Phase 1 Extension de dose
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Esophagus
Epithelial ovarian cancer
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Adenocarcinoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Xenothera SAS
Phase 1 / Phase 2
Acute leukemia
#NCT05580861
#2024-513084-38-00
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
50-60 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
FLT3-ITD
4 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2A
Required histologic types
Acute lymphoblastic leukemia (ALL)
Other acute leukemia
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT05768035
Required histologic types
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
4 recruiting sites
Smart Immune SAS
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2C
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2D
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
Other mutation
KMT2A
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2B
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT04150497
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
B-cell (B-ALL)
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Cellectis SA